Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
Location: Netherlands, Gelderland, Nijmegen
Employees: 11-50
Total raised: $47.29M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Meneldor | meneldor.n... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2021 | - | $47.29M | - |
Mentions in press and media 4
| Date | Title | Description |
| 08.09.2021 | Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor | - |
| 08.09.2021 | Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor | |
| 13.12.2018 | Dutch tech startups: The most impressive funding wins of 2018 | The Netherlands is one of the countries that has a booming startup ecosystem. The country not only encourages its residents interested in becoming entrepreneurs but also provides the visa to entrepreneurs from other regions. Eventually, it ... |
| 15.05.2018 | Medicxi, RA Capital join $30M round for Dutch biotech's late-stage transplantation med | Bringing Medicxi and RA Capital Management into the fold, Xenikos has clinched $30 million in Series B funding to push its transplantation med through the last big research lap before approaching regulators’ doors. Nijme... |